1-(1-methyl-cyclohexyl)-propan-1-one | 2890-65-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-methyl-cyclohexyl)-propan-1-one
• 英文别名: 1-(1-Methyl-cyclohexyl)-propan-1-on；Aethyl-(1-methyl-cyclohexyl)-keton；1-(1-Methylcyclohexyl)propan-1-one；1-(1-methylcyclohexyl)propan-1-one
• CAS: 2890-65-5
• 化学式: C₁₀H₁₈O
• 分子量: 154.252
• InChiKey: MFFQMMJYMNKOJT-UHFFFAOYSA-N

物化性质

• 沸点：
  157.5 °C(Press: 200 Torr)
• 密度：
  0.91490 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(1-methyl-cyclohexyl)-propan-1-one 生成 1-甲基-1-丙基环己烷
  参考文献：
  名称：

  Study in the Terpene Series. XXII.^1a Synthesis, Physical Constants and Catalytic Dehydrogenation of 1-Methyl-1-ethyl-, 1-Methyl-1-n-propyl- and 1-Methyl-1-isopropylcyclohexane^1b

  摘要：

  DOI：

  10.1021/ja01615a044
• 作为产物：
  描述：

  1-甲基环己烷羧酸 在 吡啶 、 氯化亚砜 、 copper(l) chloride 作用下， 以 乙醚 为溶剂， 生成 1-(1-methyl-cyclohexyl)-propan-1-one
  参考文献：
  名称：

  Rouzaud,J. et al., Bulletin de la Societe Chimique de France, 1965, p. 2030 - 2037

  摘要：

  DOI：

文献信息

• [EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015005901A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• Substituted hydroxamic acids and uses thereof
  申请人：Blackburn Christopher

  公开号：US20110046157A1

  公开（公告）日：2011-02-24

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物： 其中R1、R2、G、n、p和q的值如说明书所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明中的化合物的制药组合物以及使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或紊乱的方法。
• Jacquier et al., Bulletin de la Societe Chimique de France, 1956, p. 1653,1664
  作者：Jacquier et al.

  DOI：——

  日期：——
• METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM
  申请人：National Taiwan University

  公开号：US20140073611A1

  公开（公告）日：2014-03-13

  The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013106520A1

  公开（公告）日：2013-07-18

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.